API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
Details:
Ganirelix Acetate-Generic is a synthetic decapeptide with high antagonistic 6 activity against naturally occurring GnRH. It is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
Lead Product(s): Ganirelix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ganirelix Acetate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Ganirelix Acetate Injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Lead Product(s): Ganirelix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Antagonä-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023